Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2014) Nobuyuki Miyasaka et al.   Modern Rheumatology

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

(2014) Takao Koike et al.   Modern Rheumatology

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

(2011) D. T. Felson et al.   ANNALS OF THE RHEUMATIC DISEASES

Quantifying the economic burden of productivity loss in rheumatoid arthritis

(2011) I. Filipovic et al.   RHEUMATOLOGY

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

(2010) D. van der HEIJDE et al.   JOURNAL OF RHEUMATOLOGY

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

The Japanese experience with biologic therapies for rheumatoid arthritis

(2010) Tsutomu Takeuchi et al.   Nature Reviews Rheumatology

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM